vs
Side-by-side financial comparison of AMREP CORP. (AXR) and Kymera Therapeutics, Inc. (KYMR). Click either name above to swap in a different company.
AMREP CORP. is the larger business by last-quarter revenue ($14.6M vs $11.5M, roughly 1.3× Kymera Therapeutics, Inc.). AMREP CORP. runs the higher net margin — 21.6% vs -667.6%, a 689.2% gap on every dollar of revenue. On growth, AMREP CORP. posted the faster year-over-year revenue change (93.8% vs -55.3%). AMREP CORP. produced more free cash flow last quarter ($5.4M vs $-60.6M). Over the past eight quarters, Kymera Therapeutics, Inc.'s revenue compounded faster (10.1% CAGR vs -13.6%).
AMREP Corporation is a real estate and media services company based in Princeton, New Jersey, in the United States. It was founded in 1961 as The American Realty and Petroleum Corporation.
Kymera Therapeutics is a clinical-stage biopharmaceutical company specialized in developing innovative targeted protein degradation therapies. It advances a diversified pipeline of drug candidates targeting previously undruggable proteins to address unmet medical needs in oncology, autoimmune and inflammatory diseases worldwide.
AXR vs KYMR — Head-to-Head
Income Statement — Q3 FY2026 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $14.6M | $11.5M |
| Net Profit | $3.1M | $-76.6M |
| Gross Margin | — | — |
| Operating Margin | 20.6% | -736.8% |
| Net Margin | 21.6% | -667.6% |
| Revenue YoY | 93.8% | -55.3% |
| Net Profit YoY | 338.9% | -82.1% |
| EPS (diluted) | $0.58 | $-0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $14.6M | — | ||
| Q4 25 | $9.4M | — | ||
| Q3 25 | $17.9M | — | ||
| Q2 25 | $11.2M | $11.5M | ||
| Q1 25 | $7.5M | $22.1M | ||
| Q4 24 | $11.9M | $7.4M | ||
| Q3 24 | $19.1M | — | ||
| Q2 24 | $19.5M | $25.6M |
| Q1 26 | $3.1M | — | ||
| Q4 25 | $1.2M | — | ||
| Q3 25 | $4.7M | — | ||
| Q2 25 | $3.9M | $-76.6M | ||
| Q1 25 | $717.0K | $-65.6M | ||
| Q4 24 | $4.0M | $-70.8M | ||
| Q3 24 | $4.1M | — | ||
| Q2 24 | $4.1M | $-42.1M |
| Q1 26 | 20.6% | — | ||
| Q4 25 | 11.9% | — | ||
| Q3 25 | 34.4% | — | ||
| Q2 25 | 31.7% | -736.8% | ||
| Q1 25 | 5.7% | -336.8% | ||
| Q4 24 | 26.4% | -1092.2% | ||
| Q3 24 | 26.1% | — | ||
| Q2 24 | 23.9% | -198.5% |
| Q1 26 | 21.6% | — | ||
| Q4 25 | 12.8% | — | ||
| Q3 25 | 26.3% | — | ||
| Q2 25 | 34.8% | -667.6% | ||
| Q1 25 | 9.5% | -296.7% | ||
| Q4 24 | 33.9% | -956.9% | ||
| Q3 24 | 21.3% | — | ||
| Q2 24 | 21.2% | -164.0% |
| Q1 26 | $0.58 | — | ||
| Q4 25 | $0.22 | — | ||
| Q3 25 | $0.87 | — | ||
| Q2 25 | $0.73 | $-0.95 | ||
| Q1 25 | $0.13 | $-0.82 | ||
| Q4 24 | $0.75 | $-0.89 | ||
| Q3 24 | $0.76 | — | ||
| Q2 24 | $0.77 | $-0.58 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $50.0M | $335.8M |
| Total DebtLower is stronger | $21.0K | — |
| Stockholders' EquityBook value | $139.4M | $971.5M |
| Total Assets | $143.9M | $1.1B |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $50.0M | — | ||
| Q4 25 | $44.6M | — | ||
| Q3 25 | $48.9M | — | ||
| Q2 25 | $39.5M | $335.8M | ||
| Q1 25 | $36.9M | $90.0M | ||
| Q4 24 | $40.1M | $120.3M | ||
| Q3 24 | $40.4M | — | ||
| Q2 24 | $29.7M | $67.6M |
| Q1 26 | $21.0K | — | ||
| Q4 25 | $23.0K | — | ||
| Q3 25 | $25.0K | — | ||
| Q2 25 | $26.0K | — | ||
| Q1 25 | $29.0K | — | ||
| Q4 24 | $32.0K | — | ||
| Q3 24 | $34.0K | — | ||
| Q2 24 | $35.0K | — |
| Q1 26 | $139.4M | — | ||
| Q4 25 | $136.0M | — | ||
| Q3 25 | $134.7M | — | ||
| Q2 25 | $130.0M | $971.5M | ||
| Q1 25 | $126.0M | $786.2M | ||
| Q4 24 | $125.1M | $835.6M | ||
| Q3 24 | $122.2M | — | ||
| Q2 24 | $118.0M | $684.9M |
| Q1 26 | $143.9M | — | ||
| Q4 25 | $140.1M | — | ||
| Q3 25 | $140.7M | — | ||
| Q2 25 | $133.8M | $1.1B | ||
| Q1 25 | $128.9M | $918.3M | ||
| Q4 24 | $129.1M | $978.0M | ||
| Q3 24 | $127.0M | — | ||
| Q2 24 | $122.8M | $826.0M |
| Q1 26 | 0.00× | — | ||
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.4M | $-59.9M |
| Free Cash FlowOCF − Capex | $5.4M | $-60.6M |
| FCF MarginFCF / Revenue | 37.0% | -527.9% |
| Capex IntensityCapex / Revenue | 0.1% | 6.1% |
| Cash ConversionOCF / Net Profit | 1.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $20.2M | $-250.5M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $5.4M | — | ||
| Q4 25 | $-4.3M | — | ||
| Q3 25 | $9.5M | — | ||
| Q2 25 | $10.2M | $-59.9M | ||
| Q1 25 | $-3.2M | $-79.2M | ||
| Q4 24 | $-182.0K | $-61.8M | ||
| Q3 24 | $10.7M | — | ||
| Q2 24 | $10.7M | $-42.9M |
| Q1 26 | $5.4M | — | ||
| Q4 25 | $-4.3M | — | ||
| Q3 25 | $9.5M | — | ||
| Q2 25 | $9.7M | $-60.6M | ||
| Q1 25 | $-3.3M | $-79.6M | ||
| Q4 24 | $-268.0K | $-62.7M | ||
| Q3 24 | $10.7M | — | ||
| Q2 24 | $10.3M | $-47.6M |
| Q1 26 | 37.0% | — | ||
| Q4 25 | -45.9% | — | ||
| Q3 25 | 53.2% | — | ||
| Q2 25 | 86.4% | -527.9% | ||
| Q1 25 | -43.4% | -360.3% | ||
| Q4 24 | -2.3% | -848.3% | ||
| Q3 24 | 55.8% | — | ||
| Q2 24 | 52.5% | -185.7% |
| Q1 26 | 0.1% | — | ||
| Q4 25 | 0.6% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 5.2% | 6.1% | ||
| Q1 25 | 0.3% | 2.1% | ||
| Q4 24 | 0.7% | 12.7% | ||
| Q3 24 | 0.2% | — | ||
| Q2 24 | 2.3% | 18.3% |
| Q1 26 | 1.72× | — | ||
| Q4 25 | -3.54× | — | ||
| Q3 25 | 2.03× | — | ||
| Q2 25 | 2.63× | — | ||
| Q1 25 | -4.51× | — | ||
| Q4 24 | -0.05× | — | ||
| Q3 24 | 2.63× | — | ||
| Q2 24 | 2.59× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
